Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Tuesday. They presently have a $41.00 price objective on the biopharmaceutical company’s stock. Vetr‘s price objective would indicate a potential upside of 11.44% from the stock’s current price.
Other analysts have also recently issued reports about the company. Cowen and Company reissued a “buy” rating on shares of Acadia Pharmaceuticals in a report on Sunday, April 17th. Leerink Swann cut Acadia Pharmaceuticals from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $40.00 to $35.00 in a report on Tuesday, May 3rd. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $44.00 price objective on shares of Acadia Pharmaceuticals in a report on Tuesday. Needham & Company LLC reaffirmed a “buy” rating and set a $49.00 price objective on shares of Acadia Pharmaceuticals in a report on Tuesday. Finally, Zacks Investment Research cut Acadia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, May 2nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $45.90.
Shares of Acadia Pharmaceuticals (NASDAQ:ACAD) traded up 1.32% during trading on Tuesday, hitting $36.79. The stock had a trading volume of 1,380,422 shares. The stock’s 50 day moving average is $35.23 and its 200-day moving average is $28.47. The company’s market cap is $4.16 billion. Acadia Pharmaceuticals has a 12-month low of $16.64 and a 12-month high of $49.82.
In other news, EVP Glenn Baity sold 4,057 shares of Acadia Pharmaceuticals stock in a transaction on Monday, July 11th. The stock was sold at an average price of $35.00, for a total value of $141,995.00. Following the completion of the sale, the executive vice president now owns 66,978 shares of the company’s stock, valued at $2,344,230. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Other large investors have made changes to their positions in the company. Prudential Financial Inc. increased its stake in shares of Acadia Pharmaceuticals by 4.1% in the first quarter. Prudential Financial Inc. now owns 7,630 shares of the biopharmaceutical company’s stock worth $213,000 after buying an additional 300 shares in the last quarter. Mutual of America Capital Management LLC boosted its position in shares of Acadia Pharmaceuticals by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 77,957 shares of the biopharmaceutical company’s stock worth $2,779,000 after buying an additional 466 shares during the last quarter. Hollencrest Securities LLC boosted its position in shares of Acadia Pharmaceuticals by 4.4% in the second quarter. Hollencrest Securities LLC now owns 12,602 shares of the biopharmaceutical company’s stock worth $409,000 after buying an additional 532 shares during the last quarter. California Public Employees Retirement System boosted its position in shares of Acadia Pharmaceuticals by 0.5% in the fourth quarter. California Public Employees Retirement System now owns 194,000 shares of the biopharmaceutical company’s stock worth $6,916,000 after buying an additional 900 shares during the last quarter. Finally, IFP Advisors Inc boosted its position in shares of Acadia Pharmaceuticals by 28.7% in the first quarter. IFP Advisors Inc now owns 5,468 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 1,219 shares during the last quarter.
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system disorders. The Company’s lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson’s disease psychosis (PDP).
